** Brokerage Needham raises PT on medical device maker iRhythm Technologies' shares to $112 from $96; maintains "buy" rating
** Raised PT represents 14.8% upside to stock's last close
** Brokerage forecasts Q4 revenue to be more than $160 mln vs est $157.5 mln - LSEG
** IRTC's heart monitoring devices, Zio monitor and Zio AT, drove company's strength in revenue forecast - brokerage
** Company forecast 2025 revenue between $675 mln and $685 mln, brokerage expects company will make "further progress on ramping profitability"
** Company's shares fell ~11% in 2024
(Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.